Bright Minds Biosciences Inc. (DRUG) Stock Score, Valuation & Financial Research

Bright Minds Biosciences Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DRUG

Bright Minds Biosciences Inc. does not currently have a complete Wall Street Score. The stored market price is USD 49.82. These figures are a research snapshot, not a buy or sell recommendation.

What Bright Minds Biosciences Inc. does

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Company business and revenue

Research reporting period: 2025-09-30. A research update is not a new financial filing.

How the company makes money

Bright Minds Biosciences is a pre-revenue biotechnology company focused on the development of novel therapeutics for neuropsychiatric disorders, epilepsy, and pain. The company operates as a research and development entity, funding its operations through equity financing and capital markets while advancing drug candidates through preclinical and clinical trials.

Products and services

  • The company develops a portfolio of selective 5-HT receptor agonists, including BMB-101, BMB-201, and BMB-202, designed to treat epilepsy, pain, and various neuropsychiatric indications.

Customer types

Healthcare providers and patients with neuropsychiatric disorders.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct preclinical studies and clinical trials. Source

Business relationships and partnerships

  • Firefly Neuroscience — A collaboration to analyze EEG data following the BREAKTHROUGH study, a Phase 2 trial of BMB-101 in absence epilepsy and developmental epileptic encephalopathy. Source

Competitors and product-market comparisons

  • Biotechnology and pharmaceutical companies — The company competes with various entities developing therapeutics for epilepsy, pain, and neuropsychiatric disorders, which may have greater financial, technical, and human resources. Source

Business strengths to evaluate

  • Portfolio of patented, selective serotonin receptor agonists Source

Business risks and research considerations

  • History of operating losses and dependence on future financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source · Firefly Neuroscience · Portfolio of patented, selective serotonin receptor agonists

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DRUG financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 49.82
Market capitalization:
487.6M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -17.41M
Free cash flow:
USD -6.12M
Cash:
USD 216.82M
Total debt:
USD 46.22K
EPS:
USD -1.94

What stands out

  • Free cash flow is USD -6.12M, negative for the stored period.
  • The balance sheet shows USD 216.82M of cash versus USD 46.22K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 216.77M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DRUG

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can DRUG fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is DRUG likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for DRUG to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of DRUG's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research DRUG

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.